MARKET

EYPT

EYPT

Eyepoint Pharmac
NASDAQ
17.74
+1.02
+6.10%
After Hours: 17.74 0 0.00% 17:52 12/05 EST
OPEN
16.86
PREV CLOSE
16.72
HIGH
17.82
LOW
16.59
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
17.82
52 WEEK LOW
3.910
MARKET CAP
1.47B
P/E (TTM)
-5.9339
1D
5D
1M
3M
1Y
5Y
1D
EyePoint Pharmaceuticals Director Makes a Significant Stock Sale!
TipRanks · 1d ago
EyePoint Pharmaceuticals Director Nancy Lurker Reports Disposal of Common Shares
Reuters · 1d ago
Director Sells EyePoint Pharmaceuticals Shares in Notable Transaction
TipRanks · 5d ago
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential
TipRanks · 5d ago
Director Nancy Lurker Reports Sale of EyePoint Pharmaceuticals Inc. Common Shares
Reuters · 5d ago
Weekly Report: what happened at EYPT last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at EYPT last week (1117-1121)?
Weekly Report · 11/24 09:13
EyePoint Pharmaceuticals: Positive DSMC Recommendations and Promising Clinical Trials Reinforce Buy Rating
TipRanks · 11/20 11:25
More
About EYPT
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.

Webull offers Eyepoint Pharmaceuticals Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.